In vivo effect of imatinib on progression of cecal GIST-like tumors in exon 17-type c-kit knock-in mice

Laboratory Investigation

Volumn 89, Issue 10, 2009, Pages 1161-1168

  Ishikawa, Takashi ^a,b   Nakai, Norihiro ^a   Liu, Ning Ning ^a   Shiba, Kazuhiro ^a   Isozaki, Koji ^a   Matsuda, Ikuo ^a   Ito, Takashi ^a   Fujimoto, Jiro ^a   Hatakeyama, Katsuyoshi ^b   Kanda, Tatsuo ^b   Hirota, Seiichi ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

^b NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

Author keywords

C kit gene; Exon 17; GIST like tumor; Imatinib; Knock in mouse

Indexed keywords

ASPARTIC ACID; IMATINIB; KI 67 ANTIGEN; PROTEIN KINASE B; STAT1 PROTEIN; STEM CELL FACTOR; TYROSINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CECUM TUMOR; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; EXON; FEMALE; GASTROINTESTINAL STROMAL TUMOR; GERM LINE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; KNOCKOUT MOUSE; LABELING INDEX; MITOSIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR VOLUME; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CECAL NEOPLASMS; CELL PROLIFERATION; DISEASE PROGRESSION; EXONS; FEMALE; GASTROINTESTINAL STROMAL TUMORS; GENE KNOCK-IN TECHNIQUES; HETEROZYGOTE; KI-67 ANTIGEN; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MUTATION; PHOSPHORYLATION; PIPERAZINES; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; RNA, MESSENGER; SIGNAL TRANSDUCTION;

EID: 70349554663     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2009.78     Document Type: Article

References (52)

1. Hirota S, Isozaki K, Moriyama Y, et al Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998;279:577-580. (Pubitemid 28067289)
2. Kindblom LG, Remotti HE, Aldenborg F, et al Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol 1998;152:1259-1269.
3. Yarden Y, Kuang WJ, Yang-Feng T, et al Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. EMBO J 1987;6:3341-3351.
4. Chabot B, Stephenson DA, Chapman VM, et al The proto-oncogene c-kit encoding a transmembrane tyrosine kinase receptor maps to the mouse W locus. Nature 1988;335:88-89.
5. Qiu FH, Ray HP, Brown Y, et al Primary structure of c-kit: Relationship with the CSF-1/PDGF receptor kinase family-oncogenic activation of v-kit involves deletion of extracellular domain and C terminus. EMBO J 1988;7:1003-1111.
6. Geissler EN, Ryan MA, Housman DE. The dominant-white spotting (W) locus of the mouse encodes the c-kit proto-oncogene. Cell 1988;55:185-192.
7. Thomsen L, Robinson TL, Lee JC, et al Interstitial cells of Cajal generate a rhythmic pacemaker current. Nat Med 1998;4:848-851.
8. Maeda H, Yamagata A, Nishikawa S, et al Requirement of c-kit for development of intestinal pacemaker system. Development 1992;116:369-375.
9. Huizinga JD, Thuneberg L, Kluppel M, et al W/kit gene required for interstitial cells of Cajal and for intestinal pacemaker activity. Nature 1995;373:347-349.
10. Isozaki K, Hirota S, Nakama A, et al Disturbed intestinal movement, bile reflux to the stomach, and deficiency of c-kit-expressing cells in Ws/Ws mutant rats. Gastroenterology 1995;109:456-464.
11. Williams DE, Eisenman J, Baird A, et al Identification of a ligand for the c-kit proto-oncogene. Cell 1990;63:167-174.
12. Flanagan JG, Leder P. The kit ligand: a cell surface molecule altered in steel mutant fibroblasts. Cell 1990;63:185-194.
13. Zsebo KM, Williams DA, Geissler EN, et al Stem cell factor is encoded at the Sl locus of the mouse and is the ligand for the c-kit tyrosine kinase receptor. Cell 1990;63:213-224.
14. Furitsu T, Tsujimura T, Tono T, et al Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. J Clin Invest 1993;92:1736-1744.
15. Tian Q, Frierson Jr HF, Krystal GW, et al Activating c-kit gene mutations in human germ cell tumors. Am J Pathol 1999;154:1643-1647.
16. Lux ML, Rubin BP, Biase TL, et al KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. Am J Pathol 2000;156:791-795.
17. Lasota J, Wozniak A, Sarlomo-Rikala M, et al Mutations in exons 9 and 13 of KIT gene are rare events in gastrointestinal stromal tumors. Am J Pathol 2000;157:1091-1095.
18. Hirota S, Nishida T, Isozaki K, et al Gain-of-function mutation at the extracellular domain of KIT in gastrointestinal stromal tumours. J Pathol 2001;193:505-510.
19. Kinoshita K, Isozaki K, Hirota S, et al c-kit gene mutation at exon 17 or 13 is very rare in sporadic gastrointestinal stromal tumors. J Gastroenterol Hepatol 2003;18:147-151.
20. Kinoshita K, Hirota S, Isozaki K, et al Characterization of tyrosine kinase I domain c-kit gene mutation Asn655Lys newly found in primary jejunal gastrointestinal stromal tumor. Am J Gastroenterol 2007;102: 1134-1136.
21. Nishida T, Hirota S, Taniguchi M, et al Familial gastrointestinal stromal tumours with germline mutation of the KIT gene. Nature Genet 1998;19:323-324. (Pubitemid 28357901)
22. O'Brien P, Kapusta L, Dardick I, et al Multiple familial gastrointestinal autonomic nerve tumors and small intestinal neuronal dysplasia. Am J Surg Pathol 1999;23:198-204.
23. Hirota S, Okazaki T, Kitamura Y, et al Cause of familial and multiple gastrointestinal autonomic nerve tumors with hyperplasia of interstitial cells of Cajal is germline mutation of the c-kit gene. Am J Surg Pathol 2000;24:326-327.
24. Isozaki K, Terris B, Belghiti J, et al Germline-activating mutation in the kinase domain of KIT gene in familial gastrointestinal stromal tumors. Am J Pathol 2000;157:1581-1585.
25. Maeyama H, Hidaka E, Ota H, et al Familial gastrointestinal stromal tumor with hyperpigmentation: association with a germline mutation of the c-kit gene. Gastroenterology 2001;120:210-215.
26. Beghini A, Tibiletti MG, Roversi G, et al Germline mutation in the juxtamembrane domain of the kit gene in a family with gastrointestinal stromal tumors and urticaria pigmentosa. Cancer 2001;92:657-662.
27. Hirota S, Nishida T, Isozaki K, et al Familial gastrointestinal stromal tumors associated with dysphagia and novel type germline mutation of KIT gene. Gastroenterology 2002;122:1493-1499.
28. Robson ME, Glogowski E, Sommer G, et al Pleomorphic characteristics of a germ-line KIT mutation in a large kindred with gastrointestinal stromal tumors, hyperpigmentation, and dysphagia. Clin Cancer Pathol 2004;10:1250-1254.
29. Carballo M, Aguilar F, Pol MA, et al Novel c-KIT germline mutation in a family with gastrointestinal stromal tumors and cutaneous hyperpigmentation. Am J Med Genet A 2005;132:361-364.
30. Li FP, Fletcher JA, Heinrich MC, et al Familial gastrointestinal stromal tumor syndrome: phenotype and molecular features in a kindred. J Clin Oncol 2005;23:2735-2743.
31. Kim HJ, Lim SJ, Park K, et al Multipe gastrointestinal stromal tumors with a germline c-kit mutation. Pathol Int 2005;55:655-659.
32. Tarn C, Merkel E, Canutescu AA, et al Analysis of KIT mutations in sporadic and familial gastrointestinal stromal tumors: therapeutic implications through protein modeling. Clin Cancer Res 2005;11:2005.
33. Hartmann K, Wardelmann E, Ma Y, et al Novel germline mutation of KIT associated with familial gastrointestinal stromal tumors and mastocytosis. Gastroenterology 2005;129:1042-1046.
34. O'Riain C, Corless CL, Heinrich MC, et al Gastrointestinal stromal tumors: insights from a new familial GIST kindred with unusual genetic and pathologic features. Am J Surg Pathol 2005;29:1680-1683.
35. Kang DY, Park CK, Choi JS, et al Multiple gastrointestinal stromal tumors: clinicopathologic and genetic analysis of 12 patients. Am J Surg Pathol 2007;31:224-232.
36. Graham J, Debiec-Rychter M, Corless CL, et al Imatinib in the management of multiple gastrointestinal stromal tumors associated with a germline KIT K642E mutation. Arcch Pathol Lab Med 2007;131:1393-1396.
37. Wozniak A, Rutkowski P, Sciot R, et al Rectal gastrointestinal stromal tumors associated with a novel germline KIT mutation. Int J Cancer 2008;122:2160-2164.
38. Thalheimer A, Schlemmer M, Bueter M, et al Familial gastrointestinal stromal tumors caused by the novel KIT exon 17 germline mutation N822Y. Am J Surg Pathol 2008;32:1560-1565.
39. Sommer G, Agosti V, Ehlers I, et al Gastrointestinal stromal tumors in a mouse model by target mutation of the Kit receptor tyrosine kinase. Proc Natl Acad Sci USA 2003;100:6706-6711.
40. Rubin BP, Antonescu C, Scott-Browne JP, et al A knock-in mouse model of gastrointestinal stromal tumor harboring KIT K641E. Cancer Res 2005;65:6631-6639.
41. Nakai N, Ishikawa T, Nishitani A, et al A mouse model of a human multiple GIST family with KIT-Asp820Tyr mutation generated by a knock-in strategy. J Pathol 2008;214:302-311.
42. Buchdunger E, Cioffi CL, Law N, et al Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-KIT and platelet-derived growth factor receptors. J Pharmaco Exp Ther 2000;295:139-145.
43. Druker BJ, Talpaz M, Resta DJ, et al Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031-1037.
44. Van Oosterom AT, Judson I, Verweiji J, et al Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 2001;358:1421-1423.
45. Demetri GD, von Mehren M, Blanke CD, et al Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472-480.
46. Heinrich MC, Griffith DJ, Druker BJ, et al Inhibition of c-KIT receptor tyrosine activity by STI571, a selective tyrosine kinase inhibitor. Blood 2000;96:925-932.
47. Chen H, Isozaki K, Kinoshita K, et al Imatinib inhibits various types of activating mutant KIT found in gastrointestinal stromal tumors. Int J Cancer 2003;105:130-135.
48. Heinrich MC, Owzar K, Corless CL, et al Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. J Clin Oncol 2008;26: 5360-5367.
49. Rossi F, Ehlers I, Agosti V, et al Oncogenic Kit signaling and therapeutic intervention in a mouse model of gastrointestinal stromal tumor. Proc Natl Acad Sci USA 2006;103:12843-12848.
50. Antonescu CR, Besmer P, Guo T, et al Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res 2005;11:4182-4190.
51. Heinrich MC, Corless CL, Blanke CD, et al Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol 2006;24:4764-4774.
52. Nishida T, Kanda T, Nishitani A, et al Secondary mutations in the kinase domain of the KIT gene are predominant in imatinib-resistant gastrointestinal stromal tumor. Cancer Sci 2008;99: 799-804.